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Purpose: The aim of this work is to search for new metrics that could give more reliable accep-
tance/rejection criteria on the IMRT verification process and to offer solutions to the discrepancies
found among different conventional metrics. Therefore, besides conventional metrics, new ones are
proposed and evaluated with new tools to find correlations among them. These new metrics are
based on the processing of the dose–volume histogram information, evaluating the absorbed dose
differences, the dose constraint fulfillment, or modified biomathematical treatment outcome models
such as tumor control probability (TCP) and normal tissue complication probability (NTCP). An
additional purpose is to establish whether the new metrics yield the same acceptance/rejection plan
distribution as the conventional ones.
Methods: Fifty eight treatment plans concerning several patient locations are analyzed. All of them
were verified prior to the treatment, using conventional metrics, and retrospectively after the treatment
with the new metrics. These new metrics include the definition of three continuous functions, based
on dose–volume histograms resulting from measurements evaluated with a reconstructed dose system
and also with a Monte Carlo redundant calculation. The 3D gamma function for every volume
of interest is also calculated. The information is also processed to obtain ∆TCP or ∆NTCP for
the considered volumes of interest. These biomathematical treatment outcome models have been
modified to increase their sensitivity to dose changes. A robustness index from a radiobiological
point of view is defined to classify plans in robustness against dose changes.
Results: Dose difference metrics can be condensed in a single parameter: the dose difference global
function, with an optimal cutoff that can be determined from a receiver operating characteristics
(ROC) analysis of the metric. It is not always possible to correlate differences in biomathematical
treatment outcome models with dose difference metrics. This is due to the fact that the dose constraint
is often far from the dose that has an actual impact on the radiobiological model, and therefore,
biomathematical treatment outcome models are insensitive to big dose differences between the
verification system and the treatment planning system. As an alternative, the use of modified radio-
biological models which provides a better correlation is proposed. In any case, it is better to choose
robust plans from a radiobiological point of view. The robustness index defined in this work is a good
predictor of the plan rejection probability according to metrics derived from modified radiobiological
models. The global 3D gamma-based metric calculated for each plan volume shows a good correlation
with the dose difference metrics and presents a good performance in the acceptance/rejection process.
Some discrepancies have been found in dose reconstruction depending on the algorithm employed.
Significant and unavoidable discrepancies were found between the conventional metrics and the new
ones.
Conclusions: The dose difference global function and the 3D gamma for each plan volume are
good classifiers regarding dose difference metrics. ROC analysis is useful to evaluate the predictive
power of the new metrics. The correlation between biomathematical treatment outcome models and
the dose difference-based metrics is enhanced by using modified TCP and NTCP functions that
take into account the dose constraints for each plan. The robustness index is useful to evaluate
if a plan is likely to be rejected. Conventional verification should be replaced by the new met-
rics, which are clinically more relevant. C 2016 American Association of Physicists in Medicine.
[http://dx.doi.org/10.1118/1.4964796]
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1. INTRODUCTION
Prior to its delivery to a patient, any IMRT treatment designed
and calculated by a treatment planning system (TPS) must be
verified with an alternative system. To that end, calculation-
based or measurement-based approaches may be employed.
From the beginning of IMRT, a pretreatment approach has
been used in most of the cases, comparing measured dose in
selected planes or points with TPS predicted dose. Dedicated
phantoms have been used for this purpose, as well as several
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detectors such as ionization chamber arrays, diode arrays,
ionization chambers, and radiochromic or radiographic films.1
To decide whether the plan is accepted, several metrics have
been traditionally used, being one of the most popular the
gamma analysis of a planar dose in a significant plane inside a
phantom.2,3 The applied tolerance has usually been 3%–3 mm.
This gamma analysis can be performed for a whole plan
containing the sum of all the beams or individually, for a
particular beam. In addition, sometimes a composite plan with
all the beams perpendicular to the measurement plane has
been employed. Keeping in mind that this kind of gamma
analysis applies to relative dose (where the normalization
point has to be chosen carefully), the verification is usually
completed with absolute dose measurements in one or several
points with an IMRT-dedicated ionization chamber. The cutoff
point to reject a plan is set by analyzing if the percentage
of points with gamma >1 is bigger than a certain amount
(5% or 10%) or if the absolute dose measured at one point
differs more than 3% from the dose predicted by the TPS.
In this work, this kind of verification will be referred to as
“conventional verification (CONV).” If some cutoff value is
exceeded, a subsequent investigation of the cause in order
to accept the plan is necessary. From a clinical point of view,
this procedure can lead to the so-called false positives (FP) and
false negatives (FN) because as it has been stated, there may be
cases in which the measured and calculated dose distribution
differ in a significant number of points but this has no clinical
relevance and, in the opposite way, sometimes there may be
cases with few points out of tolerance but located in a clinically
relevant region of the patient (i.e., the spinal cord).4–7 The
first circumstance leads to an unnecessary drain of resources
(replan and new verification) and the second one could be
potentially risky for the patient, due to a clinical constraint
out of tolerance. In addition, when the dose distributions are
studied in 3D, the 3D gamma criterion has to be used instead,
and this may produce different results to those obtained using
planar dose distributions.4,7,8
In recent years, several systems have incorporated the
estimation of dose–volume histograms (DVH) coming from
the pretreatment measurements, by means of an appropriate
algorithm or a measurement-based dose perturbation.9–12
Simultaneously, several groups have investigated the use of
new metrics for IMRT plan verification with the aim of getting
clinically relevant results.11–16 Since the verification DVH
provides information about discrepancies in plan constraints,
the result of the plan verification can be considered more
relevant. With the differential DVH, it is possible to obtain
biomathematical treatment outcome models as equivalent
uniform dose (EUD), tumor control probability (TCP), and
normal tissue control probability (NTCP). The differences be-
tween verification and TPS calculation in these radiobiological
functions can also be used as a valid metric to investigate plan
acceptance.15 To date, it remains unclear what metrics are the
most appropriate ones, and the cutoffs are not well established
or explained.14 The DVH comparison can be performed and
complete reports generated, but it would be very useful to
rely on additional metrics to make a decision, since dose
discrepancies may not have any clinical impact, even if they
are evaluated from the DVH. In this work, new metrics are
proposed in an effort to account for this clinical impact.
Showing how the different verification metrics are related
and how new single parameters summarize the verification
outcome can provide confidence to the user. Additionally, the
generation of a cutoff value based on statistics is a common
procedure in clinical diagnosis, which is a very similar process
to the IMRT verification process. This allows the user to
effectively discern which plans would benefit the most from
further analysis.
In this paper, a “metric” is considered as a function that
arises from the comparison between two dose distributions
whose output is a continuous or binary variable.
After the IMRT commissioning at our institution, our
experience, using different verification methods available over
time, has shown that the results of plan acceptance or rejection
were contradictory in some cases, even if the same metric was
used.
Therefore, our purpose is to compare different metrics,
either dose distribution-based, DVH-based, or TCP/NTCP-
based, to establish valid cutoffs in plan acceptance and to
explore the possibility of a combined analysis, including the
use of indicators or a few parameters that can summarize the
whole verification process. Some of these metrics proposed
here are new.
2. METHODS
2.A. Treatment unit and TPS calculation
In our hospital, step-and-shoot IMRT treatments are carried
out with a Siemens Oncor Impression Plus linac equipped with
the Optifocus multileaf collimator (MLC). This collimator has
41 pairs of opposed tungsten leaves. The width at isocenter of
the 39 inner pairs is 1 cm, while that of the two outer pairs
is 0.5 cm, so that the maximum field size in the direction
perpendicular to the leaf movement is 40 cm. The leaves are
doubly focused, their thickness is 7.6 cm, and they have a
straight end. To reduce the interleaf transmission, the MLC
has been endowed with a tongue-and-groove structure (TGS):
each leaf has a tongue on one side and a groove on the other,
except for the pair of central leaves, which have a tongue on
either side. In a previous work,17 we developed a component
module for the Optifocus MLC compatible with the BEAMnrc
code. The behavior of the Optifocus MLC has been studied
previously.18,19
The TPS used to design the IMRT plans was PCRT3D
6.02 (Tecnicas Radiofisicas SL). The calculation algorithm
was the collapsed cone superposition algorithm (noted here-
after as TPS). The TPS calculations were validated using
Monte Carlo (MC) simulations performed with the BEAMnrc
code.20
2.B. Plan selection
Fifty eight IMRT plans were selected, including several
locations: neck, brain, prostate with lymph nodes, and
gynecological pelvis. The plan distribution is shown in Table I.
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T I. Distribution of plans per location and prescribed dose.
Location Total number of plans
Prescribed dose (Gy)
(number of plans)
Neck 32 70(3), 68.8(2), 67.9(1), 66(25),
60(1)
Brain 10 46(1), 42(2), 60(3), 54(1),
52(1), 50(2)
Prostate 13 76(1), 78(4), 74(2), 56(2),
50(1), 32(1), 28(1), 46(1)
Pelvis 3 50(1), 51(2)
This plan set is a representative of the IMRT treatments
delivered at our center from the moment we started to monitor
the MLC behavior until the experimental part of this study
was concluded. The chosen patients have a variable number
of PTVs and different dose prescription at each PTV. In
neck treatments, 1–3 PTVs are irradiated with an equivalent
scheme of 70, 60, and 50 Gy given in 2 Gy/fraction. These
three volumes are not always present depending on the tumor
extension. In prostate treatments, there are two volumes: one
involving lymph nodes with an equivalent dose prescription
of 46 or 50 Gy in 2 Gy/fraction, and the prostate itself, which
receives up to 78 Gy in 2 Gy fractions. In brain tumors, the
dose prescription is 60 Gy, with an external volume irradiated
up to 42 Gy in some cases. For the gynecological pelvis,
lymph nodes are irradiated up to 46–50 Gy in 2 Gy fractions
and the solid tumor is irradiated up to 60 Gy. The contoured
organs at risk are parotid glands, spinal cord, optical nerves,
chiasm, brain stem, lenses, larynx, oral cavity, mandible,
and thyroid gland for head and neck treatments, and rectum,
bladder, femoral heads, kidneys, and spinal cord for pelvic
and abdominal regions.
2.C. IMRT conventional verification
All the selected plans were measured initially with a CC01
pin-point ionization chamber (IBA dosimetry) calibrated in
dose to water. The chamber was always placed in a significant
location inside the IMRT phantom (IBA dosimetry), usually
corresponding to a point inside the PTV in the original plan,
surrounded by a homogenous dose area (i.e., less than 3%
coefficient of variation in a radius of 2 mm). The measured
dose was compared to the dose predicted by the TPS, usually
the prescription dose per fraction, and a cutoff of ±3% was
established as permitted deviation.
In addition to the ion chamber measurements, planar
analysis was performed using three different methods over
time, due to changes in available equipment. In all cases,
the fields were irradiated at their original gantry angles. The
first method was a field-by-field analysis comparing TPS
prediction with an EPID image transformed to dose using
in-house developed software.21,22 The second method was
the complete plan irradiation with a 2D ionization chamber
array (MatriXX evolution detector, IBA dosimetry) placed in
the Multicube phantom (IBA dosimetry). The third method
was the complete plan irradiation with a radiochromic film
placed inside the IMRT phantom, transforming the gray level
of the scanned film to dose following published methods.23,24
A gamma analysis with a 3%/3 mm agreement criterion
was used when comparing the measured planes to the TPS
prediction. The test was passed when the gamma passing rate
was higher than 90% (with a 10% dose threshold). In the first
method, field-by-field EPID analysis, the normalization dose
was fixed according to a significant dose inside the field map
(flat area inside the map with a significant dose, typically
over half the maximum dose). In the second and third cases,
planar MatriXX dose measurement and radiochromic film,
the normalization dose was the prescribed dose per fraction
because the whole plan was delivered to the measurement
system.
2.D. IMRT verification tools
The  system (IBA dosimetry) is a commercially
available solution which uses a 2D ionization chamber
matrix (the MatriXX, same as in Sec. 2.C). It is able to
reconstruct 3D doses in a phantom or a patient CT using
the measured signal to reconstruct a measured fluence.
This reconstructed fluence leads to a reconstructed 3D
dose by means of a beam model and a collapsed cone
superposition algorithm. Further details on this process can
be found in Godart et al.10 Hereafter the acronym CMPM
refers to this measurement-based calculation. In addition,
the system can be used separately from the detector: a
dose calculation can be performed without measurement to
provide an independent dose calculation, starting from a
theoretical fluence constructed using the RTPlan information.
The acronym CMPC refers to this RTPlan-based dose
calculation matrix. The  software also contains several
tools to analyze the data in the patient anatomy and extract
information from the DVHs. The calculated or reconstructed
3D dose matrix can be exported, and therefore it is possible
to import these CMPM and CMPC matrices in our TPS.
The  system has to be commissioned as it contains
its own calculation engine and experimental beam data must
be introduced. This commissioning process was done at our
institution prior to the beginning of this study. All the 58
plans mentioned in Sec. 2.C have been measured with 
retrospectively.
2.E. Monte Carlo calculations
To use MC as intended, it has been necessary to adapt
the BEAMnrc package to our particular MLC, developing a
new component module, and a new software application to
perform the patient dose calculation, using the RTPlan file
and the patient CT image set.17 This application generates
a dose matrix file that can be imported from the current
TPS. Therefore, MC produces a DVH set for every plan
that is subsequently compared with the TPS DVHs using
the metrics defined below. Our purpose is also to explore
the possibility of incorporating the daily linac variability
in the MC calculations. To this end, a proportional scaling in
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the MC differential DVHs is defined as follows:
∆Di =Di · D¯pPTV,CMPM− D¯pPTV,CMPCDprescribed , (1)
where Di are the MC differential histogram dose values, and
D¯pPTV,CMPM and D¯pPTV,CMPC are theaveragedoses to theprimary
PTV obtained using CMPM and CMPC, respectively. This
is an approximation that takes into account different effects
including the daily MLC leaves position, which is the most
important variability factor in our case, and allows incorporat-
ing this effect in the MC redundant calculation. We refer to the
whole process as Monte Carlo proportional scaling (MCPS),
and the DVHs coming from this process are treated as if they
werecomingfromameasurement-basedcalculationalgorithm.
2.F. Biomathematical treatment outcome models
and robustness index (IR)
For TCP and NTCP calculation, the same models proposed
in Zhen et al.15 are employed, where TCP is calculated
by means of a logit expression and NTCP is calculated
using the de Lyman–Kutcher–Burman model. The generalized
equivalent uniform dose (gEUD) can be calculated for the
PTVs and for the OARs. This is done by means of the following
equation:
gEUD= *,

i
viD
1
n
i
+-
n
, (2)
where vi is the fractional volume that receives a dose level of
Di and n is the volume effect parameter. The specific values
for the parameters used in this study to calculate gEUD are
taken from Zhen et al.15 and can be found in Table II.
m is the slope parameter specific for a tissue, inversely
proportional to the slope of the dose–response curve. In the
same table are also listed: D50, the dose which yields a tumor
control probability of 50%, γ50, the normalized slope of the
TCP curve at D50, and TD50, the dose that would cause a
T II. List of parameters used in radiobiological calculations.
Organ D50/TD50 (cGy) γ50 n (1/a) m
H&N PTV 5044 1.73 −0.1
Prostate PTV 7050 2.66 −0.1
Brain PTV 4800 2 −0.1
Lung PTV 5100 1.6 −0.1
Rectum 7200 0.06 0.15
Bladder 6200 0.13 0.11
Femoral head 6500 0.25 0.12
Cord 6650 0.05 0.175
Brain stem 7000 0.05 0.18
Parotid 2840 1 0.18
Lens 1250 0.3 0.27
Optical nerve 6500 0.25 0.14
Heart 4800 0.35 0.1
Kidney 4000 0.7 0.1
Chiasm 6500 0.25 0.14
Small bowel 5500 0.15 0.16
50% chance of normal tissue complication, if the entire organ
is uniformly irradiated to that dose. They are employed as
in Zhen et al.15 for the TCP and NTCP calculations. Here,
the robustness index concept is introduced. It is associated to
the plan robustness initially described in Zhen et al.15 as a
quantitative way to integrate the concept of plan robustness
into the treatment planning process to improve the quality
of radiotherapy plans and make them robust to perturbations
as far as possible. We suggest a mathematical expression for
this index, developed in several steps. First of all, it would be
necessary to adapt the dose–response curves to the imposed
dose constraints, introducing a shift on them until they are
situated in a dose variation sensitive region. The motivation for
that is that TCP and NTCP are not sensitive to dose changes if
D50 and TD50 are not similar to the dose constraint established
for the evaluated organ. Sometimes the prescribed dose is
not the complete treatment dose, for instance, when IMRT is
applied as a boost or in a plan that is going to be completed
with brachytherapy. In addition, a 50% complication for some
organs at risk (i.e., spinal cord and larynx) should not be
assumed, which implies the constraint is always situated
far away from a significant complication dose. To increase
the TCP and NTCP sensitivity, D50 and TD50 parameters
can be adapted to the plan constraints. This is an artificial
and mathematical trick, and it leads to new biomathematical
functions that we call modified TCP and NTCP, TCPMOD
and NTCPMOD, respectively, built using conveniently chosen
values for D50,MOD and TD50,MOD, respectively. For TD50,MOD,
the chosen values, noted as Dv,c, can be found in Table III and
correspond to the dose plan constraint (c) at each particular
volume of interest (VOI) (v).
For D50,MOD, the chosen value is the 80% of the prescribed
dose. That locates the TCPMOD dose–response curve in an
adequate region for each plan.
Modified TCP and NTCP functions lose, of course, their
radiobiological meaning but are considered to be better
predictors of the plan viability. The curve slopes are calculated
using gEUD. Taking the same equations for the TCP and
NTCP as in Zhen et al.,15 the partial derivative of TCPMOD for
every PTV is evaluated. First, gEUD is calculated following
Eq. (2), and then, the TCP logit expression when the fractional
T III. IMRT plan constraints (Dv,c) extracted from the DVH analysis.
Organs at risk Constraint
Brain stem D1 < 53 Gy
Optical nerves and chiasm D1 < 49.25 Gy
Spinal cord D1 < 44.5 Gy
Parotid glands Average dose < 26 Gy
Lenses D1 < 8 Gy
Rectum D20 < 70 Gy
Bladder D30 < 70 Gy
PTV Constraint
Constraint 1 D95 > 95% prescribed dose
Constraint 2 Average dose > 0.97∗ prescribed dose
Constraint 3 D2 < 110% prescribed dose
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volume is 1 is derived, as all voxels are supposed to have the
gEUD,
∂TCPMOD, i
∂gEUDi
=
4 ·D50,MOD ·
(
D50,MOD
gEUDi
)4·γ50−1 ·γ50(
1+
(
D50,MOD
gEUDi
)4·γ50)2 ·gEUDi2 . (3)
The same process is applied to NTCP and a partial derivative
can be defined using TD50,MOD,
∂NTCPMOD, i
∂gEUDi
=
0.399 · e
− (gEUDi−TD50,MOD)2
2·m2·TD250,MOD
m ·TD50,MOD . (4)
The TCPMOD and NTCPmod curves reach their maximum slope
when gEUD=D50,MOD for the PTV and gEUD=TD50,MOD for
the OARs, respectively. These values are
∂TCPi,MOD
∂gEUDi max
=
γ50
D50,MOD
and
∂NTCPi,MOD
∂gEUDi max
=
0.399
m ·TD50,MOD .
First, gEUD is evaluated for every organ for a given plan,
and this value is used to evaluate the TCP and NTCP curve
slope at the considered point. Then, the ratio to the maximum
slope is calculated and all the components for every volume i
are multiplied, being N the total number of organs, including
PTV. The robustness index is defined as
RI=
N
i=1
*.,1−
∂XCPi,MOD
∂gEUDi
∂XCPi,MOD
∂gEUDi max
+/-. (5)
Note that the first initial of the modified radiobiological index
has been noted as “X ,” which indicates that may be substituted
by “T” or “NT” depending on the considered volume, PTV
or OAR. RI is zero if one of the considered volumes has a
gEUD that equals D50,MOD or TD50,MOD. In this case, a plan is
classified as “barely robust.” A plan is “robust,” i.e., RI close
to 1, if none of the calculated slopes for the modified TCP or
NTCP curves approaches to the D50,MOD or TD50,MOD values,
respectively. In addition, a plan with an organ receiving a dose
that is significantly higher than the dose constraint would also
be a robust plan. For instance, if one of the two parotid glands is
close to the tumor, accepting its loss enables the average dose
to be considerably higher than the dose constraint (usually
26 Gy). In this case, RI will not be affected by significant dose
variations involving this particular parotid gland.
2.G. Proposed metrics
IMRT verification is similar to a diagnosis problem. One
has to evaluate if the result of the applied test is positive or
negative, i.e., if the considered plan is rejected or accepted.
When studying a set of cases and two metrics to classify them,
contingency tables can be established, if it is assumed for
convenience that one of the metrics is the reference metric. In
this work, as stated in the Introduction, a metric is given always
by a variable, and this variable can be continuous or binary.
T IV. Generic contingency table.
Reference variable
Contingency table Positive 0 Negative 1 Total
Tested variable Positive 0 TP FP TP + FP
Negative 1 FN TN FN + TN
Total Positives Negatives Total cases
In Table IV, a generic contingency table is shown between
binary variables (0 is taken as positive or, in our case, plan
rejection and 1 is taken as negative or plan acceptance). In
this kind of table, there are two binary variables compared,
one set as reference and the other set as tested. Every variable
has its own positives and negatives and the reference variable
is the one that classifies the results of the tested variable into
false results (FN, FP) or true results (TN, TP, true negatives or
positives).
For metrics that are represented by continuous variables,
it is always possible to discretize the variable in finite
steps, once a cutoff value is fixed. For metrics that are
represented by binary variables, one may vary the cutoff value
that defines the acceptance/rejection criteria and build a set
of contingency tables based on different cutoffs. A binary
variable is constructed based on the cases that have a value
under or over the cutoff.
In this work, we propose and define new metrics that can
be calculated from the DVHs and the IMRT plan constraints.
These metrics are based on continuous or binary variables.
First, three new continuous functions are defined. The purpose
of these functions is to synthesize in a few parameters the
differences found between the DVHs coming from verification
dose matrix and those coming from the TPS algorithm. The
first two functions are defined for every algorithm separately.
To evaluate them, the constraints in Table III and the values
obtained for the same evaluation points in the DVH for the
considered algorithm are used. The third function does not use
the constraints but directly compares the DVH values obtained
from two different algorithms. Let N be the total number of
constraints.
Therefore, we define these three functions as follows:
— The weighted noncompliance function, WNCF, defined
for a particular algorithm with an output dose matrix,
as the quadratic sum of the differences between the
evaluation doses at DVH points defined in Table III
and the dose constraints (c) that are shown in the same
table for each volume v . The difference contributes only
if the constraint is not fulfilled,
WNCF=
100 ·

N
v=1
wvδv,c (Dv,eval−Dv,c)2
Dprescribed
, (6)
where
δv,c = 1 if DPTV,eval < DPTV,c (average dose and D95)
or D2PTV,eval > D2PTV,c or DOAR,eval > DOAR,c
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δv,c = 0 if DPTV,eval > DPTV,c (average dose and D95)
or D2PTV,eval < D2PTV,c or DOAR,eval < DOAR,c. The
subindex v stands for a PTV or for an OAR. It can
take three values in the case of a primary PTV (D95,
average dose, and D2) or two values (D95 and average
dose), if it is a secondary PTV. The sum is normalized
to the primary PTV prescription dose. The constant
wv is employed as a weight that takes into account
if one constraint is to be considered more restrictive
than another. An adequate set of wv is going to be
investigated in this work. Six different sets are proposed
(see Table V). These sets are guessed sets where
different possibilities of PTV-OAR relative importance
are explored. For instance, set 1 and set 2 change the
relative importance of the clinical constraints among
OARs, while the other four sets explore the PTV-OAR
balance. The results of this method may depend on the
selection of the weighting set.
As mentioned above, WNCF is calculated indepen-
dently for every algorithm; therefore, the subindex eval
is employed, which stands for the evaluation method,
and it can be the one used for the verification (verif) or
the TPS algortihm.
Consequently, WNCF will exist for both systems,
being noted as WNCFverif and WNCFTPS. The differ-
ence ∆WNCFverif = WNCFverif −WNCFTPS measures
the deterioration found in the verification due to the
nonfulfillment of the constraints. The subindex “verif”
can be substituted by the name of the verification
algorithm employed, thus giving rise to two variables,
namely, ∆WNCF_CMPM and ∆WNCF_MCPS.
— The dose difference constraints-based global function,
CGF, is defined as the sum of the differences between
the dose values presented in Table III and the dose
values taken from the DVH at the same evaluation
points. This function is different from WNCF because
the constraints do not have to be necessarily unfulfilled
to obtain a contribution in every evaluation point;
therefore, this contribution can be positive or negative,
CGF=
100 · N
v=1
k · (Dv,c−Dv,eval)
Dprescribed
, (7)
where k = 1 if v corresponds to an OAR or a D2 from
the primary PTV and k = −1 if v corresponds to an
average dose or a D95 from a PTV.
CGF is defined for every separated algorithm, in
the same way as WNCF. CGF is normalized to a
percentage relative to the prescribed dose. Again,
∆CGFverif = CGFverif −CGFTPS is a measurement of
the discrepancy between verification system and TPS
calculation. The subindex verif can be substituted by the
name of the verification algorithm employed giving rise
to two variables, ∆CGF_CMPM and ∆CGF_MCPS.
— Dose difference global function, GF, is defined as the
sum with its sign of the differences extracted from the
DVH obtained with the verification algorithm (MCPS
T V. Different weighting sets for the WNCF. Every row corresponds to
a different constraint. The order is as follows: PTV (average dose, D95, and
D2 with the same weight), brain stem (D1), spinal cord (D1), rectum (D20),
bladder (D30), parotid gland (average dose), lens (D1), optical nerve (D1),
and chiasm (D1).
Set1 Set2 Set3 Set4 Set5 Set6
wmptv 1 1 0.001 1000 0,5 1
wbsd1 0.04 0.4 1 0.1 2 1
wcordd1 0.075 0.75 1 0.1 2 1
wrd20 0.05 0.5 1 0.1 2 1
wbd30 0.05 0.5 1 0.1 2 1
wparad 0.05 0.5 1 0.1 2 1
wlend1 0.025 0.25 1 0.1 2 1
wond1 0.04 0.4 1 0.1 2 1
wchid1 0.04 0.4 1 0.1 2 1
or CMPM) and the TPS algorithm. These differences
are taken into account only if they correspond to
the deterioration of the ability to meet constraints
in Table III, i.e., decreased PTV coverage, increased
PTV hotspots, or increased dose to the OARs at the
constraint levels listed in Table III. This function
directly compares the results from two algorithms;
therefore, it is the metric that measures the differences
found in the verification. GF does not use the dose
constraint values, but only the evaluation points defined
in Table III (i.e., D95, average dose, and D2 for the
PTV, and D1, D20, D30, or average dose depending
on the evaluated OAR),
GF=
100 · N
v=1
δverif,TPS(Dv,verif−Dv,TPS)
Dprescribed
. (8)
δverif,TPS=−1 if DPTV,verif < DPTV,TPS for PTV average
dose and D95
δverif,TPS = 1 if DOAR,verif > DOAR,TPS or D2PTV,verif >
D2PTV,TPS
δverif,TPS = 0 if DOAR,verif < DOAR,TPS or DPTV,verif >
DPTV,TPS for PTV average dose and D95
GF can be applied to the CMPM-TPS comparison or to
the MCPS-TPS comparison giving rise to two variables:
GF_CMPM and GF_MCPS.
These three functions, WNCF, CGF, and GF, are clinically
relevant. For instance, if the primary PTV has a higher D95 in
the verification DVH set than in the one coming from the TPS,
this fact is not penalized because this kind of dose difference
is not considered as detrimental.
Apart from these three functions, other metrics are going
to be applied to the plan verification process. The first two
of the following metrics will be used as convenient reference
metrics in this study:
— Dose difference metric (DDM). It is a binary variable
that depends on the evaluation of the TPS DVH
and the verification DVH at the points established in
Table III. The plan is accepted (negative→ 1) when
the deterioration, if produced, is less than 3% of
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the prescribed dose at all these points. Otherwise,
the plan is rejected (positive → 0). In this context,
“deterioration” means a lower verification dose at
the PTVs for D95 and average dose, and a higher
verification dose at D2 for the PTVs and at the OARs for
any defined dose constraint. If the PTV is a secondary
one, the D2 constraint is not taken into account. The
binary variable associated is called DDM_CMPM and
DDM_MCPS, depending on the algorithm which is
being compared with the TPS.
— Constraint-based dose difference metric (CDDM). The
previous metric may yield a rejection for plans that,
however, might be acceptable from a clinical point
of view. For instance, let us consider that the plan
verification is for a brain tumor treatment, and a
5% global dose increase has been obtained in the
D1 parameter for the brain stem. If the D1 was 35
Gy according to the TPS data, the verification D1
would be around 37 Gy. This means plan rejection
under the DDM metric but, unless there is any other
verification issue, the consequences to the patient would
be negligible because the dose constraint is D1< 50 Gy.
In this perspective, a metric taking into account the
plan constraints can be defined, and that means that
the plan is rejected only when the dose differences
lead to the nonfulfillment of the constraints. The
associated binary variables are CDDM_CMPM and
CCDM_MCPS. They should produce as many accepted
plans as DDM_CMPM and DDM_MCPS or more, but
never less.
— Volumes of interest 3D gamma function-based metric.
This metric is built by evaluating the 3D global
gamma function (3%–3 mm) for PTVs, OARs, and
BODY contours, and calculating the percentage gamma
rejection rate for each volume. It is only available for
the CMPM algorithm. When one VOI or more have a
rejection rate over a fixed cutoff X , the metric yields
the plan rejection. The normalization dose value in the
gamma test is assigned to the prescribed dose.
— ∆TCP and ∆NTCP are the increments that evaluate
the difference found in the verification between the
verification algorithm and TPS from a radiobiological
point of view. For the modified TCP and NTCP, the
metric is evaluated in the same way. The binary metric
based on these increments works this way: a plan
is accepted if ∆TCP > −X and, at the same time,
∆NTCP < X for all the PTVs and organs analyzed,
X being a certain value, expressed in percentage.
The value X can be varied to construct a discrete
function to be used as a classifier in the receiver
operating characteristics (ROC) analysis (Sec. 2.H).
Two binary variables are defined, ∆TCP/NTCP and
∆TCPMOD/NTCPMOD corresponding to nonmodified or
modified functions, respectively. They can be applied to
CMPM-TPS differences or to MCPS-TPS differences.
The notation ∆TCP/NTCP indicates that ∆TCP and
∆NTCP are evaluated at the same time for the plan
volumes.
— For the robustness index, ∆RI is defined as a contin-
uous metric that quantifies RI difference between the
verification algorithm and the TPS.
— There is also a binary variable associated to the
conventional verification, which takes into account
the procedure explained above (Sec. 2.C). CONV
is 1 (acceptance) when the dose measured with the
ionization chamber is within ±3% of the TPS predicted
dose and when the gamma passing rate in the measured
planes is over 90%, while CONV is 0 (rejection) if any
of these conditions are not met. This planar analysis
includes only one of the three methods described in
Sec. 2.C depending on the measurement date.
A complete summary of all the proposed metrics is
presented in Table VI.
DDM and CDDM try to mimic the medical physicist
process of assessing the DVH-based plan verification. Both
variables are based on the dose comparison at certain DVH
critical points. This is the reason why they are used for
convenience as reference variables in the subsequent statistical
analysis.
2.H. Statistical analysis
A set of contingency tables representing different cutoff
levels can be treated with ROC analysis, which measures
T VI. Summary of metrics and notation.
Metric Description Associated binary variables
∆WNCF Weighted noncompliance function ∆WNCF_CMPM, ∆WNCF_MCPS
∆CGF Dose difference constraints-based global
function
∆WNCF_CMPM, ∆WNCF_MCPS
GF Dose difference global function GF_CMPM, GF_MCPS
DDM Dose difference metric DDM_CMPM, DDM_MCPS
CDDM Constraint-based dose difference metric CDDM_CMPM, CDDM_MCPS
VOI 3Dgamma Volumes of interest 3D gamma function VOI_3Dgamma
∆TCP/NTCP Differences in TCP and NTCP between
verification algorithm and TPS
∆TCP/NTCP_CMPM, ∆TCP/NTCP
_MCPS, ∆TCPMOD/NTCPMOD_CMPM,
∆TCPMOD/NTCPMOD_MCPS
∆RI Difference in robustness index ∆RI _CMPM, ∆RI_MCPS
CONV Conventional verification CONV
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the predictive power of a variable in relation to the accep-
tance/rejection criteria of a certain reference classification
variable. This has been done for the metrics defined in
Table VI in two senses, continuous variables predicting binary
variable results and binary variables predicting binary variable
results. Each of the continuous functions defined above,
∆WNCF, ∆CGF, and GF, is used as input in the ROC analysis
proposed, evaluating their performance when predicting the
results of the binary variables DDM_MCPS, DDM_CMPM,
CDDM_MCPS, and CDDM_CMPM. As a consequence, a
geometrically optimal cutoff point (OCP) value and the area
under the curve (AUC) are obtained. For a given ROC curve,
the geometrically OCP corresponds to the point along the
curve farthest from the diagonal random guess line. AUC
measures the probability that a positive (under the reference
variable) randomly chosen from the sample will have a higher
value of the classifying continuous variable than a negative
chosen in the same way (assuming a positive yields a higher
value than a negative because the opposite may occur).
Common statistical software, the statistical package for the
social sciences () for Windows v15.0, is employed to do
this kind of ROC analysis.
On the other hand, a set of contingency tables with a binary
variable can be generated if the cutoff is changed progres-
sively. A ROC curve can be built where every point corre-
sponds to a different cutoff value. This has been done with
VOI_3Dgamma, ∆TCP/NTCP, and ∆TCPMOD/NTCPMOD.
For this curves, an OCP is also extracted. In the case of binary
variables with varying cutoff, the ROC curve is built manually
with a spreadsheet. The AUC can be integrated subsequently.
Note that once an OCP value has been obtained for
the ROC curve, a derived binary variable can be defined
classifying plans with values over/under the OCP (see
Sec. 3.E) for the metric used as input in the ROC analysis.
Consequently, the following binary variables are defined:
GF_CMPM_OCP, GF_MCPS_OCP, VOI_3Dgamma_OCP,
∆TCPMOD/NTCPMOD_CMPM_OCP, ∆TCPMOD/NTCPMOD_
MCPS_OCP, ∆RI_CMPM_OCP, and ∆RI_MCPS_OCP.
They will be used with the explicit OCP value obtained in
the ROC analysis.
The correlation between binary variables is as well
investigated. The chi-squared test for categorical data with one
degree of freedom is used. If the p-value of the chi-squared test
is less than 0.05 (associated with a high chi-squared value),
the variables are not considered to be independent in relation
to the plan classification into accepted or rejected plans. On
the other hand, if p-value is higher than 0.05, the two binary
variables considered classify the plans in a very different
way.
3. RESULTS
3.A. Best weights (wv) for WNCF
As mentioned before, the ROC analysis has been employed
to determine the best set of weights of those listed in Table V.
The reference metric role can be played by DDM_CMPM or,
alternatively, DDM_MCPS. In this case, the continuous vari-
ables investigated are ∆WNCF_CMPM and ∆WNCF_MCPS
as described in Sec. 2.G.
The results are shown in Fig. 1. The weighting set that
better predicts the behavior of the dose difference metrics is
the number 2, as it presents the best balanced AUC considering
both investigated cases. This optimal weighting set might be
dependent on the chosen patient data set; therefore, it cannot
be generalized to other cases.
3.B. Best continuous function
The predictive power of ∆WNCF (with weighting set
number 2), ∆CGF, and GF, the continuous functions defined
in Sec. 2.G, has been investigated. The ROC analysis for these
F. 1. ROC curves for the increment in ∆WNCF depending on the chosen weighting set. Two binary variables are used as reference, DDM_MCPS (a) and
DDM_CMPM (b), and the respective continuous functions (∆WNCF_MCPS and ∆WNCF_CMPM) are used as predictors. The best balanced set is the number 2,
based on AUC values.
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F. 2. ROC curves for the three continuous functions proposed as predictors, ∆WNCF, ∆CGF, and GF. Four binary variables are used as reference,
DDM_MCPS (a), CDDM_MCPS (b), DDM_CMPM (c), and CDDM_CMPM (d). AUC is shown for all the predictors, and OCP is shown in every graph
only for the best predictor, GF.
three continuous functions when used to predict the dose
difference metrics and the constraint-based dose difference
metrics for both algorithms, CMPM and MCPS (see also
Sec. 2.G), is displayed in Fig. 2.
The results indicate clearly that GF has the better perfor-
mance at predicting the dose difference metrics. GF has in any
case the biggest AUC and can be employed as an excellent
classifier from the point of view of the dose difference metrics.
The OCP (defined in Sec. 2.H) found for GF is 6.35, and this
is valid for the four ROC curves where GF is involved, given
the fact that their AUC differs only slightly among them. The
performance of ∆WNCF and ∆CGF is poorer and the reason
for this might be that they use the constraints Dv,c to calculate
the contributions for the verification and TPS algorithms.
Additionally, CGF gets a contribution from every evaluation
point in Table III, and this means that, whenever there is
an improvement in the comparison between verification and
TPS, the deterioration in other points may happen to cancel
out.
3.C. VOI 3D gamma function
The prediction of the 3D gamma function evaluated in
every patient volume of interest with respect to the dose
difference metrics binary variables is shown in Fig. 3. The
gamma rejection rate values are identified with the variable
cutoff to build the ROC curves. The values are 1%, 5%, 7.5%,
10%, 15%, 25%, 30%, and 100%. There is a good correlation
between VOI 3D gamma function and DDM_CMPM or
CDDM_CMPM. Moreover, the optimal cutoff point for VOI
3Dgamma, in both cases, corresponds to a rejection rate of
10%. At this point, the sensitivity is around 80% and the
specificity is around 90%.
3.D. Biomathematical treatment outcome models
and robustness index
In Fig. 4, the results regarding the predictive power of
∆TCP/NTCP and ∆TCPMOD/NTCPMOD, defined in Sec. 2.G,
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F. 3. ROC curves for the VOI 3Dgamma function, built by chang-
ing the acceptance threshold. Two binary variables are used as reference,
DDM_CMPM and CDDM_CMPM. The OCP for the two curves is 10%
(rejection rate for the VOI 3Dgamma function).
are presented. The variables taken as reference are the
constraint-based dose difference metrics, CDDM_MCPS
[Fig. 4(a)] and CDDM_CMPM [Fig. 4(b)], corresponding
to the reference algorithms MCPS and CMPM, respectively.
The chosen values for the cutoff to build the ROC curves are
1%, 2%, 3%, 5%, 7%, 9%, 12%, and 15%. The percentages
refer to allowed ∆TCP or ∆NTCP.
The performance of ∆TCP/NTCP for both algorithms
is poor and the AUC is below 0.7 in both cases. This
was expected from the lack of sensitivity of TCP and
NTCP to certain dose changes as described in Sec. 2.E.
It is also difficult to establish a useful cutoff value. If
TCPMOD and NTCPMOD are used instead, the result is better,
which suggests that the correlation between biomathematical
models and dose differences is improved by the modification.
AUC is 0.73 for ∆TCPMOD/NTCPMOD_MCPS predicting
CDDM_MCPS and 0.79 for ∆TCPMOD/NTCPMOD_CMPM
predicting CDDM_CMPM. OCP is 2% for both curves. How-
ever, although the improvement in correlation is noticeable,
it is clear that the behavior of dose difference metrics and
biomathematical model-based metrics is not equivalent.
3.E. Correlations
As stated above, certain OCP have been obtained for
several continuous variables used as input in the ROC
analysis. For GF, OCP = 6.35; for VOI_3Dgamma, OCP =
10%; and for ∆TCPMOD/NTCPMOD, OCP = 2%. Therefore,
five binary variables are obtained based on these thresholds:
GF_CMPM_6.35, GF_MCPS_6.35, VOI_3Dgamma_10,
∆TCPMOD/NTCPMOD _CMPM_2, and ∆TCPMOD/NTCPMOD
_MCPS_2. Note that VOI 3D gamma is only calculated for
the CMPM algorithm.
The correlations between each pair of binary variables can
be found in Table VII. This table presents a lot of condensed
information regarding the plan classification comparison
process. Every figure in bold in the table reflects a discrepancy
that has to be investigated, keeping in mind that significance
over 0.05 suggests independence of the plan classification
made by a particular couple of variables. Following this
criterion, two main discrepancies are observed: first, the
conventional verification is mainly independent from the new
metrics defined and second, some of the metrics coming from
MCPS do not correlate properly with those coming from
CMPM.
3.F. Robustness index, RI
The increment in the robustness index between the verifica-
tion algorithm (CMPM or MCPS) and the TPS algorithm,∆RI,
has also been used to predict the outcome of CDDM_CMPM
and CDDM_MCPS. The associated binary variable is ∆RI
F. 4. ROC curves for the ∆TCP/NTCP and ∆TCPMOD/NTCPMOD functions, built by changing the acceptance threshold. Two binary variables are used as
reference, CDDM_MCPS (a) and CDDM_CMPM (b). The OCP for ∆TCPMOD/NTCPMOD is shown, being 2% for both algorithms (MCPS and CMPM).
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T VII. Crossed table with chi-squared test signification and chi-squared value in brackets. Significations above 0.05 are in bold, indicating variables that
can be considered independent, and therefore the plan classification arising from them is not correlated.
DDM_CMPM CDDM_MCPS VOI_3Dgamma_10 CONV
∆TCPMOD/
NTCPMOD
_CMPM_2
∆TCPMOD/
NTCPMOD
_MCPS_2 GF_MCPS_6.35 GF_CMPM_6.35
DDM_CMPM 0 0.02(5.395) 0.0(24.1) 0.014(6.086) 0.0(18.196) 0.684(0.165) 0.009(6.880) 0.0(32.905)
CDDM_MCPS 0 0.082(3.017) 0.346(0.888) 0.196(1.673) 0.007(7.184) 0(23.196) 0.032(4.576)
VOI_3Dgamma10 0 0.157(2.002) 0.0(13.771) 0.044(4.06) 0.009(6.880) 0.0(32.905)
CONV 0 0.118(2.438) 0.409(0.683) 0.049(3.88) 0.182(1.782)
∆TCPMOD/NTCPMOD
_CMPM_2
0 0.012(6.348) 0.008(7.117) 0.0(24.939)
∆TCPMOD/NTCPMOD
_MCPS_2
0 0(16.276) 0.087(2.923)
GF_MCPS_6.35 0 0.003(9.024)
GF_CMPM_6.35 0
_CMPM_0.05 or ∆RI _MCPS_0.05, depending on the algo-
rithm. For them, the plan is rejected (positive), if two
conditions are met simultaneously for the TPS: RI< 0.05 and
∆RI< 0. Moreover, the plan is also rejected if ∆RI < −0.05.
Otherwise the plan is accepted. Due to the poor performance
of ∆RI _CMPM or ∆RI _MCPS in the ROC analysis, there
was not a consistent OCP value for them; therefore, the
cutoff choice has been made by analyzing the RI for the 58
studied plans, which present very low RI values. Equation (5)
is used for the evaluation, and when one of the DVH
values is close to the established constraint, RI quickly
approaches zero. Thus, a plan is considered barely robust when
RI< 0.05.
It follows from the above considerations that ∆RI is
not a good plan acceptance/rejection predictor. However, RI
calculated for the TPS plan seems to be a good indicator of the
probability of plan acceptance. For instance, Table VIII shows
the ability of RI to predict the output of two binary variables,
∆TCPMOD/NTCPMOD_CMPM_2 and ∆TCPMOD/NTCPMOD_
CMPM_5, which are the variables associated to the OCP
and the variable associated to a 5% increment, respectively.
In the table, the distribution of plans which were accepted
or rejected under these metrics is shown, depending on
whether they were deemed to be robust or barely robust. For
∆TCPMOD/NTCPMOD_CMPM_5, more plans are accepted,
regardless of them being robust or just barely robust, but
the rejection probability still continues to be higher for
the barely robust plans. Thus, RI has a good sensitivity
detecting plans that are likely to fail the test but a poor
specificity.
4. DISCUSSION
In this work, new metrics for the evaluation of IMRT
verification are proposed and tested. They can be used as plan
classifiers when dealing with pretreatment “step and shoot”
IMRT verification, or even in any verification that involves
DVH comparison, such as 3D dose reconstruction from EPID
in vivo dosimetry.25 Moreover, the metrics and their meaning
may be applied to other techniques such as dynamic IMRT
or VMAT, where verification measurements are commonly
employed.
It has been shown that, if a continuous function depends
on several parameters, it is possible to use the AUC coming
from the ROC analysis to determine the best set for these
parameters, provided that the range of the parameters is
properly chosen.
Also based on the ROC analysis, it is possible to evaluate
the ability of new continuous variables or a set of binary
variables to reproduce the plan classification obtained by
a reference metric. We have tested whether the verification
T VIII. TPS Plan robustness distribution with respect to the modified TCP/NTCP functions results
(∆TCPMOD/NTCPMOD_CMPM_2 and ∆TCPMOD/NTCPMOD_CMPM_5), see Sec. 2.G for the variables defini-
tion. The classification (noted as 0 = rejection or 1 = acceptance for the binary variables) defines a probability for
the rejection of the plan. Plans barely robust (RI < 0.05) are likely to be rejected.
Number of plans
∆TCPMOD/NTCPMOD
_CMPM_2 = 0
∆TCPMOD/NTCPMOD
_CMPM_2 = 1 Rejection probability (%)
Barely robust 21 18 3 85.7
Robust 37 19 18 51
Number of plans
∆TCPMOD/NTCPMOD
_CMPM_5 = 0
∆TCPMOD/NTCPMOD
_CMPM_5 = 1 Rejection probability (%)
Barely robust 21 13 8 61.9
Robust 37 8 29 22
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process can be condensed in only one parameter, and it was
found that a dose difference GF is a good predictor not
only of dose difference metrics but also of those coming
from biomathematical treatment outcome models. GF is
calculated using the DVH information with the evaluation
of the verification and TPS algorithm at particular points as
those defined in Table III. This can be generalized for a wider
constraint set. The GF cutoff value, 6.35 in our case, depends
on the threshold employed in the dose difference metrics
(3% global dose). GF is very simple to calculate and does
not need further data processing like the gamma function or
others.
Regarding the use of biomathematical models, when
implementing TCP and NTCP as new QA metrics, their
uncertainties need to be taken into account based on the
uncertainties of the model parameters. In this work, we have
found differences between the dose difference metric results
and the ∆TCP/NTCP metrics (Sec. 3.D). Although in Zhen
et al.,15 in an in silico study, the biomathematical treatment
outcome models are shown to be sensitive and specific to
differences between TPS and measurements, in clinical cases
the correlation between both kinds of metrics is weak. There
are several reasons for that: the dose difference metrics are
based on clinical constraints that may not be in the sensitive
region of the dose–response curve, the IMRT plan prescribed
dose sometimes is not a curative dose or corresponds to a boost
or an initial treatment phase, or a big maximum inside the
PTV contributes exactly in the opposite direction when using
the dose difference metrics or the ∆TCP/∆NTCP metrics.
Following these considerations, the correlation between the
two kinds of metrics is improved by defining the modified
TCP and NTCP, although the results are only partially
successful when trying to mimic the dose difference metrics.
The PTV coverage losses that generate plan rejection in
CDDM_CMPM do not always produce the same effect
on ∆TCPMOD/NTCPMOD_CMPM_X . For instance, a PTV
coverage loss over 3% in D95 or 5% in D99 means a 2% loss
in TCPMOD, indicating less sensitivity to this kind of changes.
In addition, the OCP of 2% for ∆TCPMOD/NTCPMOD_CMPM
possesses a low specificity (60%), resulting in a higher number
of false positives when compared to the dose difference
metric. The rationale behind this is that now the NTCPMOD
dose–response curve is very steep in the proximity of the
constraint. Therefore, for the OARs, the dose differences are
going to be amplified in ∆NTCPMOD. It should also be noted
that the parameters in TCP and NTCP models are fitted from
clinical data, and, therefore, are associated with their own
uncertainties.
Furthermore, in Zhen et al.,15 a pretreatment quantification
of plan robustness is proposed. Here, a mathematical form is
given to this concept through the robustness index, and there
is a correlation between this parameter and the probability of
plan rejection.
Regarding 3D gamma analysis (Sec. 3.C), good predictive
power has been found for the VOI 3D gamma using the
metric VOI_3Dgamma_10, relative to the dose difference
metrics. In principle, some excess of false positives would
be expected because the gamma function does not make the
difference between dose difference sign while DDM_CMPM
and DDM_MCPS do. However, when OARs are receiving
lower doses following the verification algorithm, the same
often occurs with the PTV coverage. This is because, in
our case, the main cause of discrepancies between TPS
prediction and verification is the MLC leaves position19
(real average position of leaves compared to the TPS
predicted position), which influences the verification process
by simultaneously lowering (closed leaves) or increasing
(open leaves) the dose to PTV and OARs. As found
by other authors,20 Optifocus MLC quality assurance for
IMRT requires frequent and critical assessment of MLC leaf
position calibration errors that may appear in many different
ways.
The study of the correlations among binary variables
leads to several valuable results (Sec. 3.E). First of all,
the algorithm employed in 3D dose reconstruction from
measurements influences the verification outcome. As shown
in Table VII, MCPS and CMPM lead to a different plan
classification depending on the metrics compared. Even those
pairs of metrics with a chi-squared significance lower than
0.05 may present this behavior. For instance, GF_CMPM_6.35
and GF_MCPS_6.35 differ in the classification in 29% of
the plans, although chi-squared significance is 0.003. One
may think that this is due to the partial correction made
on MCPS because only daily linac behavior is taken into
account, but further investigations have revealed that the
origin of the main discrepancies is derived from the MC vs
CMPC comparison, i.e., Monte Carlo redundant calculation
compared to the  dose calculation engine, which does
not depend on measurements. This result is in agreement
with those of other authors.26 As stated in this study, an
independent calculation algorithm in the dose reconstruction
might lead to additional discrepancy in the verification results,
if the dose reconstruction computation is not accurate enough.
Additional uncertainties can be introduced by this kind of
algorithms.
In regard to the conventional verification, deep disagree-
ment in plan classification has been found when comparing to
the new metrics, either coming from CMPM or from MCPS
(Table VII). The new metrics yield always a higher number
of rejected plans. The rationale behind this is that DVH-based
metrics are more sensitive to delivery problems because they
evaluate several points and they are more likely to fail than the
conventional verification, where the ionization chamber is usu-
ally inside the PTV and the 2D gamma planar verification is not
correlated to dose errors in anatomic regions-of-interest.5,11
When measuring the previously approved treatments with
the  system, we found that several plans had some
issues based on the DVH verification, especially involving the
PTV coverage. In our case, the old metrics were generating
a significant number of false negatives, which means low
sensitivity. This can be concluded also from the work of Stasi6
that showed a low sensitivity if 3%/3 mm global gamma
was employed, leading to a disputable predictive power for
perpatient IMRT QA. Apart from that, some contribution to the
disagreement could be explained by the fact that conventional
and  measurements were not coincident in time.
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As a corollary to the DVH-based metrics analysis, there
is not a complete equivalence among them, suggesting that
there is not a completely reliable metric. This arises from
the fact that biomathematical function differences have an
intrinsically different behavior than dose difference metrics,
and also from the fact that a plan failing under DDM or
CDDM could be accepted if other indicators as GF or
VOI_GAMMA3D show a value below the cutoff. Moreover,
no one can guarantee that a dose difference is always clinically
relevant. Nonetheless, the recommendation is not to avoid the
use of DDM or CDDM, for they are valid metrics to evaluate
the plan deliverability, but other presented metrics can provide
additional and valuable information and eventually change an
initial acceptance/rejection decision.
Finally, a recommendation of IMRT pretreatment verifica-
tion can be made based on our findings: first, select the most
robust plans that can be obtained from the TPS, then evaluate
subsequently the dose difference GF and VOI 3Dgamma (if
possible). If the obtained values are under the cutoffs, the
plan may be accepted. Otherwise, further investigation of the
causes that produce the plan rejection under those functions is
needed.
5. CONCLUSION
New IMRT verification metrics have been proposed and
their relation and acceptance/rejection predictive power has
been assessed. The ROC analysis has been proved especially
useful to find classifiers and evaluate their power. The dose
difference GF and the VOI 3Dgamma are good classifiers
regarding dose difference metrics and a rejection cutoff can be
defined for them. The correlation between biomathematical
treatment outcome models and the dose difference-based
metrics is improved by using modified TCP and NTCP
functions which take into account the plan constraints. The
robustness index, specifically calculated for each plan can be
used to predict how high the rejection probability is under
modified TCP and NTCP metrics. Conventional verification
has to be replaced by the new metrics, which are more relevant
from a clinical point of view.
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